RW
Elite in Acute Myeloid Leukemia (AML)

Dr. Roland B. Walter

Hematology And Hematologic Malignancy Clinic At SCCA
Seattle, WA
Elite
 in Acute Myeloid Leukemia (AML)
Specialties:Hematology
Experience:27 Years
Age:53
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

View 10 More Conditions +
Check Dr. Roland B. Walter's experience treating your condition:
About Dr. Roland B. Walter

Roland Walter is a Hematologist in Seattle, Washington. Walter has been practicing medicine for over 27 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 17 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Washington. Walter is currently accepting new patients.

His clinical research consists of co-authoring 232 peer reviewed articles and participating in 24 clinical trials in the past 15 years. In particular, he has co-authored 199 articles and participated in 24 clinical trials in the study of Acute Myeloid Leukemia (AML).

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Roland B. Walter it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
825 Eastlake Ave E, Seattle, WA 98109
Background & Education
Graduate Institution
Other, 1996
Specialties
Hematology
Licenses
Internal Medicine in WA
Hospital Affiliations
Seattle Cancer Care Alliance
UW Medical Center - Montlake
Languages Spoken
English
French
German
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Biological, Drug
Study Drugs: VOR33Mylotarg
Study Phase: Phase 1/Phase 2
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Enrollment Status: Recruiting
Publish Date: September 09, 2022
Intervention Type: Other, Biological, Drug
Study Drugs: Liposomal DaunorubicinLiposomal CytarabineCladribineCytarabineGranulocyte Colony-Stimulating FactorMitoxantrone
Study Phase: Phase 2
A Long-term Follow-up Study of Patients Who Received VOR33
Enrollment Status: Recruiting
Publish Date: August 10, 2022
Intervention Type: Genetic
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: May 24, 2022
Intervention Type: Procedure, Drug
Study Drugs: CytarabineDaunorubicin HydrochlorideGemtuzumab OzogamicinMidostaurin
Study Phase: Phase 1
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: May 27, 2021
Intervention Type: Drug
Study Drugs: AzacitidineIMGN632Venetoclax
Study Phase: Phase 1/Phase 2
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Enrollment Status: Active, not recruiting
Publish Date: November 04, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: CladribineCytarabineGemtuzumabGranulocyte Colony-Stimulating FactorMitoxantrone
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: January 18, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Procedure, Other
Study Phase: Phase 2
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug, Biological, Other
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: January 10, 2020
Intervention Type: Biological, Drug, Other
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: May 23, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality
Enrollment Status: Completed
Publish Date: May 25, 2018
Intervention Type: Drug, Other
Study Phase: Not Applicable
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: May 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study
Enrollment Status: Terminated
Publish Date: July 02, 2017
Intervention Type: Drug, Procedure
Study Phase: Phase 1/Phase 2
Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: June 01, 2017
Intervention Type: Drug, Other
Study Phase: Phase 2
Assessment of Stem Cell Heterogeneity in AML in Co-Culture Systems Using X Chromosome Inactivation Patterns
Enrollment Status: Completed
Publish Date: July 11, 2016
Intervention Type: Other, Genetic
S0106B, Stem Cell Origin in AML: Prognostic and Therapeutic Implications
Enrollment Status: Completed
Publish Date: March 06, 2015
Intervention Type: Other, Genetic
Pilot Study of Feasibility, Safety, and Economics of Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Non-APL Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 19, 2011
Intervention Type: Other, Procedure
Study Phase: Not Applicable
View 15 Less Clinical Trials -
232 Total Publications
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Journal: Leukemia & lymphoma
Published: October 13, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
SM
Dr. Soheil S. Meshinchi
Pediatric Hematology Oncology | Hematology | Oncology
Elite
Highly rated in
14
conditions
Pediatric Hematology Oncology
Hematology
Oncology

SCCA Wellness Center At South Lake Union

1100 Fairview Ave N, 
Seattle, WA 
 0.1 mi

Soheil Meshinchi is a Pediatric Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Meshinchi has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 14 other conditions, according to our data. His top areas of expertise are Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Megakaryoblastic Leukemia, Leukemia, and Bone Marrow Transplant. He is licensed to treat patients in Washington. Meshinchi is currently accepting new patients.

PH
Dr. Paul C. Hendrie
Hematology
Elite
Highly rated in
22
conditions
Hematology

Hematology And Hematologic Malignancy Clinic At SCCA

825 Eastlake Ave E, 
Seattle, WA 

Paul Hendrie is a Hematologist in Seattle, Washington. Hendrie has been practicing medicine for over 28 years and is rated as a Distinguished expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 22 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration. He is licensed to treat patients in Washington. Hendrie is currently accepting new patients.

EK
Dr. Elizabeth F. Krakow
Hematology | Hematology Oncology
Distinguished
Highly rated in
12
conditions
Hematology
Hematology Oncology

Seattle Cancer Care Alliance

825 Eastlake Ave E, 
Seattle, WA 

Elizabeth Krakow is a Hematologist and a Hematologist Oncology expert in Seattle, Washington. Krakow has been practicing medicine for over 20 years and is rated as a Distinguished expert by MediFind in the treatment of Acute Myeloid Leukemia (AML). She is also highly rated in 12 other conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant. She is licensed to treat patients in Washington. Krakow is currently accepting new patients.